摘要
目的 观察地榆升白片联合重组人粒细胞集落刺激因子(rhG-CSF)治疗肺癌化疗后骨髓抑制(LCCABMS)临床疗效。方法 将我院60例LCCABMS患者随机分为对照组与观察组各30例。对照组采用rhG-CSF治疗,观察组在对照组治疗基础上联合地榆升白片治疗。比较两组Karnofsky预后评分(KPS)优良率,血清白细胞计数(WBC)、中性粒细胞计数(NEUT)、血红蛋白(Hb)、血小板计数(PLT)及中医证候评分,不良反应发生率。结果 治疗后,观察组KPS优良率高于对照组(P<0.05);两组WBC、NEUT、Hb、PLT水平低于治疗前,观察组WBC、NEUT、Hb、PLT水平高于对照组(P<0.05);两组中医证候评分低于治疗前,观察组中医证候评分低于对照组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论 地榆升白片联合rhG-CSF治疗LCCABMS的疗效显著,能延缓外周血细胞下降幅度,对改善中医证候有良好的效果,安全性良好。
Objective To observe the efficacy of Diyu Shengbai Tablets combined with recombinant human granulocyte colony-stimulating factor(rhG-CSF)in treatment of bone marrow suppression(LCCABMS)after chemotherapy for lung cancer.Methods A total of 60 patients with LCCABMS were randomly divided into control group and observation group,with 30 cases in each group.Control group was treated with rhG-CSF,while observation group was treated with Diyu Shengbai Tablets on the basis of control group.The excellent rate of Karnofsky prognostic score(KPS),serum white blood cell count(WBC),neutrophil count(NEUT),hemoglobin(Hb),platelet count(PLT),TCM syndrome score,and incidence of adverse reactions were compared between the two groups.Results After treatment,the excellent rate of KPS in observation group was higher than that in control group(P<0.05);the levels of WBC,NEUT,Hb,and PLT in both groups were lower than those before treatment,which were higher in observation group than control group(P<0.05);the TCM pattern score of both groups was lower than that before treatment,which were lower in observation group than control group(P<0.05),and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Diyu Shengbai Tablets combined with rhG-CSF has significant efficacy on LCCABMS,which can delay the decline of peripheral blood cells,and has a good effect on improving TCM syndrome with good safety.
作者
赵润泽
靳华龙
周咏春
ZHAO Run-ze;JIN Hua-long;ZHOU Yong-chun(Anhui Provincial Linquan County People’s Hospital,Fuyang 236400;First Affiliated Hospital of Bengbu Medical University,Bengbu 233004)
出处
《湖北中医药大学学报》
2025年第4期17-20,共4页
Journal of Hubei University of Chinese Medicine
基金
安徽省阜阳市卫生健康科研项目(项目编号:FY2024-039)
关键词
肺癌
化疗后
骨髓抑制
地榆升白片加减
重组人粒细胞集落刺激因子
Lung cancer
After chemotherapy
Bone marrow suppression
Modified Diyu Shengbai Tablets
Granulocyte colony-stimulating factor
